Down's syndrome and Alzheimer's disease: Towards secondary prevention

Nature Reviews Drug Discovery

Volumn 11, Issue 9, 2012, Pages 655-656

  Ness, Seth ^a   Rafii, Michael ^a   Aisen, Paul ^a   Krams, Michael ^a   Silverman, Wayne ^a   Manji, Husseini ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; CONDITIONING; DEMENTIA; DOWN SYNDROME; EARLY INTERVENTION; HUMAN; IMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; REVIEW; SECONDARY PREVENTION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; DOWN SYNDROME; GENETIC MARKERS; GENOTYPE; HUMANS; SECONDARY PREVENTION;

EID: 84866138083     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3822     Document Type: Review

References (5)

1. Jonsson, T. et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96-99 (2012).
2. Zigman, W., Silverman, W. & Wisniewski, H. M. Aging and Alzheimer's disease in Down syndrome: clinical and pathological changes. Mental Retard. Dev. Disabilities Res. Rev. 2, 73-79 (1996).
3. Zigman, W. B. & Lott, I. T. Alzheimer's disease in Down syndrome: neurobiology and risk. Mental Retard. Dev. Disabilities Res. Rev. 13, 237-246 (2007).
4. Shi, Y. et al. A human stem cell model of early Alzheimer's disease pathology in Down syndrome. Sci. Transl. Med. 4, 124ra29 (2012).
5. Barker, A. D. et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin. Pharmacol. Ther. 86, 97-100 (2009).